VANDA PHARMACEUTICALS INC. Increase (Decrease) in Other Operating Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Other Operating Liabilities of $267.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2015-03-13
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for the quarter ending 2014-12-31 was $103.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for the quarter ending 2014-09-30 was $46.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for the quarter ending 2014-06-30 was $168.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for the quarter ending 2014-03-31 was -$50.00K, a 124.04% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for fiscal 2014 was $267.00K, a 156.73% increase from fiscal 2013.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for fiscal 2013 was $104.00K, a 60.75% decline from fiscal 2012.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for fiscal 2012 was $265.00K, a 37.50% decline from fiscal 2011.
- VANDA PHARMACEUTICALS INC. increase (decrease) in other operating liabilities for fiscal 2011 was $424.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2014-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $149.00K derived: sum of 2 quarters · filed 2015-03-13 | $317.00K derived: sum of 3 quarters · filed 2015-03-13 | $267.00K 10-K · filed 2015-03-13 |
| 2014-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $214.00K derived: sum of 2 quarters · filed 2014-10-27 | $164.00K 10-Q · filed 2014-10-27 | $113.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2014-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $118.00K 10-Q · filed 2014-08-08 | $67.00K derived: sum of 3 quarters · filed 2015-03-13 | $16.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2014-03-31 | -$50.00K 10-Q · filed 2014-05-08 | -$101.00K derived: sum of 2 quarters · filed 2015-03-13 | -$152.00K derived: sum of 3 quarters · filed 2015-03-13 | -$154.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$102.00K derived: sum of 2 quarters · filed 2015-03-13 | -$104.00K derived: sum of 3 quarters · filed 2015-03-13 | $104.00K 10-K · filed 2015-03-13 |
| 2013-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | -$53.00K derived: sum of 2 quarters · filed 2014-10-27 | $155.00K 10-Q · filed 2014-10-27 | $363.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $206.00K 10-Q · filed 2014-08-08 | $414.00K derived: sum of 3 quarters · filed 2015-03-13 | $622.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $208.00K 10-Q · filed 2014-05-08 | $416.00K derived: sum of 2 quarters · filed 2015-03-13 | $624.00K derived: sum of 3 quarters · filed 2015-03-13 | $834.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $416.00K derived: sum of 2 quarters · filed 2015-03-13 | $626.00K derived: sum of 3 quarters · filed 2015-03-13 | $265.00K 10-K · filed 2015-03-13 |
| 2012-09-30 | $208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $418.00K derived: sum of 2 quarters · filed 2013-11-08 | $57.00K 10-Q · filed 2013-11-08 | $371.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | -$151.00K 10-Q · filed 2013-07-31 | $163.00K derived: sum of 3 quarters · filed 2014-02-25 | $292.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | -$361.00K 10-Q · filed 2013-05-10 | -$47.00K derived: sum of 2 quarters · filed 2014-02-25 | $82.00K derived: sum of 3 quarters · filed 2014-02-25 | $71.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $443.00K derived: sum of 2 quarters · filed 2014-02-25 | $432.00K derived: sum of 3 quarters · filed 2014-02-25 | $424.00K 10-K · filed 2014-02-25 |
| 2011-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $118.00K derived: sum of 2 quarters · filed 2012-11-08 | $110.00K 10-Q · filed 2012-11-08 | $106.00K derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$19.00K 10-Q · filed 2012-08-03 | -$23.00K derived: sum of 3 quarters · filed 2013-02-26 | -$27.00K derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | -$8.00K 10-Q · filed 2012-05-09 | -$12.00K derived: sum of 2 quarters · filed 2013-02-26 | -$16.00K derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$8.00K derived: sum of 2 quarters · filed 2013-02-26 | -$17.00K 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$13.00K 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$9.00K 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $5.00K 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |